AUPH Quote, Financials, Valuation and Earnings

ESSA Pharma has a net margin of 21.17% compared to Aurinia Pharmaceuticals's net margin of --. Aurinia Pharmaceuticals's return on equity of -5.99% beat ESSA Pharma's return on equity of --.

Aurinia Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 20%. On the other hand ESSA Pharma has an analysts' consensus of -- which suggests that it could grow by 492.85%. Given that ESSA Pharma has higher upside potential than Aurinia Pharmaceuticals, analysts believe ESSA Pharma is more attractive than Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals has a beta of 1.408, which suggesting that the stock is 40.752% more volatile than S&P 500. In comparison ESSA Pharma has a beta of 1.624, suggesting its more volatile than the S&P 500 by 62.388%.

Aurinia Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ESSA Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurinia Pharmaceuticals pays -- of its earnings as a dividend. ESSA Pharma pays out -- of its earnings as a dividend.

Aurinia Pharmaceuticals quarterly revenues are $67.8M, which are larger than ESSA Pharma quarterly revenues of --. Aurinia Pharmaceuticals's net income of $14.4M is higher than ESSA Pharma's net income of -$6.4M. Notably, Aurinia Pharmaceuticals's price-to-earnings ratio is -- while ESSA Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurinia Pharmaceuticals is 5.92x versus -- for ESSA Pharma. Usually stocks with elevated PS ratios are considered overvalued.

ImmunoPrecise Antibodies has a net margin of 21.17% compared to Aurinia Pharmaceuticals's net margin of -41.68%. Aurinia Pharmaceuticals's return on equity of -5.99% beat ImmunoPrecise Antibodies's return on equity of -68.99%.

Aurinia Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 20%. On the other hand ImmunoPrecise Antibodies has an analysts' consensus of -- which suggests that it could grow by 1149.69%. Given that ImmunoPrecise Antibodies has higher upside potential than Aurinia Pharmaceuticals, analysts believe ImmunoPrecise Antibodies is more attractive than Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals has a beta of 1.408, which suggesting that the stock is 40.752% more volatile than S&P 500. In comparison ImmunoPrecise Antibodies has a beta of 0.210, suggesting its less volatile than the S&P 500 by 79.036%.

Aurinia Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ImmunoPrecise Antibodies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurinia Pharmaceuticals pays -- of its earnings as a dividend. ImmunoPrecise Antibodies pays out -- of its earnings as a dividend.

Aurinia Pharmaceuticals quarterly revenues are $67.8M, which are larger than ImmunoPrecise Antibodies quarterly revenues of $4.5M. Aurinia Pharmaceuticals's net income of $14.4M is higher than ImmunoPrecise Antibodies's net income of -$1.9M. Notably, Aurinia Pharmaceuticals's price-to-earnings ratio is -- while ImmunoPrecise Antibodies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurinia Pharmaceuticals is 5.92x versus 0.61x for ImmunoPrecise Antibodies. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience has a net margin of 21.17% compared to Aurinia Pharmaceuticals's net margin of -2121.06%. Aurinia Pharmaceuticals's return on equity of -5.99% beat Lexaria Bioscience's return on equity of -93.31%.

Aurinia Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 20%. On the other hand Lexaria Bioscience has an analysts' consensus of -- which suggests that it could grow by 348.43%. Given that Lexaria Bioscience has higher upside potential than Aurinia Pharmaceuticals, analysts believe Lexaria Bioscience is more attractive than Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals has a beta of 1.408, which suggesting that the stock is 40.752% more volatile than S&P 500. In comparison Lexaria Bioscience has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.234%.

Aurinia Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurinia Pharmaceuticals pays -- of its earnings as a dividend. Lexaria Bioscience pays out -- of its earnings as a dividend.

Aurinia Pharmaceuticals quarterly revenues are $67.8M, which are larger than Lexaria Bioscience quarterly revenues of $84K. Aurinia Pharmaceuticals's net income of $14.4M is higher than Lexaria Bioscience's net income of -$1.8M. Notably, Aurinia Pharmaceuticals's price-to-earnings ratio is -- while Lexaria Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurinia Pharmaceuticals is 5.92x versus 59.30x for Lexaria Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals has a net margin of 21.17% compared to Aurinia Pharmaceuticals's net margin of --. Aurinia Pharmaceuticals's return on equity of -5.99% beat Xenon Pharmaceuticals's return on equity of --.

Aurinia Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 20%. On the other hand Xenon Pharmaceuticals has an analysts' consensus of $57.67 which suggests that it could grow by 49.05%. Given that Xenon Pharmaceuticals has higher upside potential than Aurinia Pharmaceuticals, analysts believe Xenon Pharmaceuticals is more attractive than Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals has a beta of 1.408, which suggesting that the stock is 40.752% more volatile than S&P 500. In comparison Xenon Pharmaceuticals has a beta of 1.189, suggesting its more volatile than the S&P 500 by 18.926%.

Aurinia Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurinia Pharmaceuticals pays -- of its earnings as a dividend. Xenon Pharmaceuticals pays out -- of its earnings as a dividend.

Aurinia Pharmaceuticals quarterly revenues are $67.8M, which are larger than Xenon Pharmaceuticals quarterly revenues of --. Aurinia Pharmaceuticals's net income of $14.4M is higher than Xenon Pharmaceuticals's net income of -$62.8M. Notably, Aurinia Pharmaceuticals's price-to-earnings ratio is -- while Xenon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurinia Pharmaceuticals is 5.92x versus 222.63x for Xenon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.